<DOC>
	<DOCNO>NCT00598702</DOCNO>
	<brief_summary>Intravenous acetaminophen ( IVAPAP ) safe repeat dose , multi-day clinical use administer daily dose 40 75 mg/kg body weight</brief_summary>
	<brief_title>Study Safety &amp; Efficacy Intravenous Acetaminophen Pediatric Inpatients</brief_title>
	<detailed_description>To assess safety intravenous acetaminophen ( IV APAP ) use one day treatment acute pain fever pediatric ( neonate , infant , child adolescent ) inpatient unable take anything mouth ( NPO ) , require would benefit IV treatment , willing able stay IVAPAP therapy 1 7 day .</detailed_description>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>The Subject 's Parent Guardian must provide write informed consent , Subject assent appropriate , prior Subject 's participation Study . Be le 17 year age old 37 week post conception Anticipated Investigator require multiday ( minimum one day ) use intravenous ( IV ) treatment either status nothing mouth ( NPO ) medical condition make oral intake difficult willing undergo least 5 day treatment IV acetaminophen treatment pain fever Have ability read understand Study procedure ability communicate meaningfully Study Investigator staff ( Subject preverbal age read communicate meaningfully , Subject 's Parent Guardian must meet criterion ) If female child bear potential , negative pregnancy test Has significant medical disease ( ) , laboratory abnormality condition ( ) Investigator 's judgment could compromise Subject 's welfare , ability communicate Study staff , complete Study activity , would otherwise contraindicate Study participation Has know hypersensitivity contraindication receive IV acetaminophen inactive ingredient ( excipients ) IV acetaminophen Has impair liver function , e.g . Alanine aminotransferase ( ALT ) great equal 3 time upper limit normal ( ULN ) , bilirubin great equal 3 time ULN , know active hepatic disease ( e.g. , hepatitis ) , evidence clinically significant chronic liver disease condition affect liver ( e.g. , alcoholism define Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) , cirrhosis , chronic hepatitis ) may suggest potential increased susceptibility hepatic toxicity IV acetaminophen exposure Has participate interventional clinical Study ( investigational market product ) within 30 day Study entry</criteria>
	<gender>All</gender>
	<minimum_age>37 Weeks</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>